Morepen Laboratories Ltd

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Morepen Laboratories declined 22.54% to Rs 15.74 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales rose 4.05% to Rs 484.72 crore in the quarter ended March 2026 as against Rs 465.85 crore during the previous quarter ended March 2025. For the full year,net profit declined 19.61% to Rs 94.88 crore in the year ended March 2026 as against Rs 118.02 crore during the previous year ended March 2025. Sales declined 0.33% to Rs 1805.69 crore in the year ended March 2026 as against Rs 1811.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales484.72465.85 4 1805.691811.58 0 OPM %5.049.07 -6.969.61 - PBDT29.0342.18 -31 130.52184.09 -29 PBT23.2925.71 -9 94.09155.11 -39 NP15.7420.32 -23 94.88118.02 -20 Powered by Capital Market - Live

Morepen Laboratories has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 26 May 2026.

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Morepen Laboratories announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its Masulakhanna (HP) facility, with Zero observations (NIL Form 483). This marks the Fourth consecutive NIL 483 inspection for Morepen over the past eight years, underscoring the Company's unwavering commitment to global quality and regulatory standards.

Morepen Laboratories has repaid working capital demand loan facility and cash credit limit availed from Kotak Mahindra Bank amounting to Rs 79 crore on 02 March 2026. Powered by Capital Market - Live

Blue Jet Healthcare Ltd, BLS International Services Ltd, CIE Automotive India Ltd and Kitex Garments Ltd are among the other gainers in the BSE's 'A' group today, 23 February 2026.Morepen Laboratories Ltd surged 15.01% to Rs 45.21 at 11:45 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 46.1 lakh shares were traded on the counter so far as against the average daily volumes of 1.4 lakh shares in the past one month. Blue Jet Healthcare Ltd soared 9.95% to Rs 390.8. The stock was the second biggest gainer in 'A' group. On the BSE, 88032 shares were traded on the counter so far as against the average daily volumes of 31068 shares in the past one month. BLS International Services Ltd spiked 8.23% to Rs 290.65. The stock was the third biggest gainer in 'A' group. On the BSE, 13.23 lakh shares were traded on the counter so far as against the average daily volumes of 5.42 lakh shares in the past one month. CIE Automotive India Ltd exploded 7.07% to Rs 502.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.5 lakh shares were traded on the counter so far as against the average daily volumes of 15656 shares in the past one month. Kitex Garments Ltd added 6.15% to Rs 197.55. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.24 lakh shares were traded on the counter so far as against the average daily volumes of 2.48 lakh shares in the past one month. Powered by Capital Market - Live

The company stated that the supplies under the said mandate are expected to commence within the next 4'5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. Morepen Labs further said that this engagement marks one of the most significant single CDMO mandates in the Company's history, as it scales its global manufacturing footprint. Sushil Suri, chairman & managing director, said: This mandate represents an important milestone in the evolution of Morepen's manufacturing platform. We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses. Morepen Laboratories is a vertically integrated pharmaceutical and healthcare company delivering APIs, branded generics, medical devices, and consumer wellness products worldwide. The company's consolidated net profit rose 3.07% to Rs 27.51 crore on a 6.93% increase in revenue to Rs 484.16 crore in Q3 FY26 as compared with Q3 FY25. On the BSE, over 20.92 lakh shares of the company had changed hands at the counter as compared with the average trading volume of 1.56 lakh shares. In the last one year, the scrip has lost 12.08% while the benchmark S&P BSE Sesnex and the S&P BSE Healthcare index have gained 11.90% and 9.85%, respectively. Powered by Capital Market - Live

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharma major. Supplies under the mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.Powered by Capital Market - Live

Net profit of Morepen Laboratories rose 3.07% to Rs 27.51 crore in the quarter ended December 2025 as against Rs 26.69 crore during the previous quarter ended December 2024. Sales rose 6.93% to Rs 484.16 crore in the quarter ended December 2025 as against Rs 452.78 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales484.16452.78 7 OPM %9.577.98 - PBDT45.8040.14 14 PBT35.4235.21 1 NP27.5126.69 3 Powered by Capital Market - Live